ΣΦ-1401

ΣΦ-1401 is a proprietary development code for a pharmaceutical product within the pipeline of Sigmapharm Laboratories. It is categorized as a unique generic or branded product currently being prepared for regulatory submission via the Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) pathways. The specific active pharmaceutical ingredient (API), therapeutic indication, and molecular target are not publicly disclosed by the company. Sigmapharm identifies the product as possessing barrier-to-entry properties, which typically refers to complexities in formulation, bioavailability, stability, or intellectual property that limit competition in the generic market. As of the company's last public pipeline update in October 2018, the asset was tracked through various stages of regulatory preparation, including feasibility and formulation.